Kezar Life Sciences Inc [KZR] stock is trading at $1.02, down -0.97%. An important factor to consider is whether the stock is rising or falling in short-term value. The KZR shares have gain 13.81% over the last week, with a monthly amount glided 7.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024, at 10:30 a.m. ET.
From an analyst’s perspective:
Kezar Life Sciences Inc [NASDAQ: KZR] stock has seen the most recent analyst activity on August 11, 2023, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $4 for it. Previously, William Blair downgraded its rating to Mkt Perform on March 16, 2023. On December 08, 2021, Wells Fargo initiated with a Overweight rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating. Wells Fargo initiated its recommendation with a Outperform and recommended $30 as its price target on July 16, 2018.
Kezar Life Sciences Inc [KZR] stock has fluctuated between $0.67 and $5.96 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Kezar Life Sciences Inc [NASDAQ: KZR] shares were valued at $1.02 at the most recent close of the market. An investor can expect a potential return of 1615.69% based on the average KZR price forecast.
Analyzing the KZR fundamentals
Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -13.84%, Pretax Profit Margin comes in at -12.54%, and Net Profit Margin reading is -12.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.35 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9737 points at the first support level, and at 0.9275 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0631, and for the 2nd resistance point, it is at 1.1063.
Kezar Life Sciences Inc [KZR] reported earnings per share of -$0.32 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.35/share, meaning a difference of $0.03 and a surprise factor of 8.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.34 per share as compared to estimates of -$0.32 per share, a difference of -$0.02 representing a surprise of -6.30%.
Ratios To Look Out For
For context, Kezar Life Sciences Inc’s Current Ratio is 13.83. On the other hand, the Quick Ratio is 13.83, and the Cash Ratio is 1.59. Considering the valuation of this stock, the price to sales ratio is 10.61, the price to book ratio is 0.34.
